The objective of HEOR and RWD was initially to better reflect patient outcomes in the real-world and validate clinical trials. Pharma companies typically use this information for product promotion, however the initial purpose of the research is often lost with customers and stakeholders not seeing the results as valuable. Based on my work at Syneos Health, HEOR is not a US-centric activity as health insurers have not been receptive to Quality-of-Life (QoL) or cost information in any case that we tested. I argue that companies seeking a global presence at any point in their future will need to invest in hiring, training, and innovation in this field.
The purpose of this poster is a three-fold progression: (1) to identify the appropriate disease-specific QoL measurement instruments, (2) explore whether the clinical outcomes observed (safety, efficacy) are related to the changes in QoL, (3) to choose the QoL measurement instrument that best reflects the patient health state. The insights on how this research can be applied at an organizational level are outlined at the bottom of the poster.